Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 6th Annual Israel Conference

Rhea-AI Summary

Xenetic Biosciences (NASDAQ: XBIO) will host a live video webcast featuring CEO Jeffrey Eisenberg on November 12, 2020, at 8:00 AM EST during the H.C. Wainwright 6th Annual Israel Conference. The event will highlight advancements in the XCART™ personalized CAR T platform, targeting tumor-specific neoantigens for B-cell lymphomas. Following the presentation, management will engage in virtual one-on-one meetings with registered investors. A replay of the webcast will be available two hours post-event and archived for 90 days.

- Live video webcast with CEO, Jeffrey Eisenberg, on Tuesday, November 12^th at 8:00 AM EST -

FRAMINGHAM, MA / ACCESSWIRE / November 5, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced today that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at the H.C. Wainwright 6^th Annual Israel Conference on Tuesday, November 12, 2020 at 8:00 AM EST.

In addition to the presentation, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

A live video webcast of the presentation will be available on the IR Calendar page of the Investors section of the Company's website (xeneticbio.com). The video webcast replay will be made available two hours following the event and will be archived for 90 days.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART™ has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Additionally, Xenetic is leveraging PolyXen®, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen® has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and receives royalty payments under this agreement.

For more information, please visit the Company's website at www.xeneticbio.com and connect on Twitter, LinkedIn, and Facebook.

Contact:

JTC Team, LLC
Jenene Thomas
(833) 475-8247
xbio@jtcir.com

SOURCE: Xenetic Biosciences, Inc.

View source version on accesswire.com:
https://www.accesswire.com/614432/Xenetic-Biosciences-Inc-to-Present-at-the-HC-Wainwright-6th-Annual-Israel-Conference

FAQ

What is the date and time for the Xenetic Biosciences webcast?

The live video webcast will occur on November 12, 2020, at 8:00 AM EST.

Who will be presenting for Xenetic Biosciences at the conference?

CEO Jeffrey Eisenberg will be presenting at the H.C. Wainwright 6th Annual Israel Conference.

What is the focus of the XCART™ platform presented by Xenetic?

XCART™ is focused on targeting patient- and tumor-specific neoantigens for the treatment of B-cell lymphomas.

How can investors access the webcast by Xenetic Biosciences?

Investors can access the webcast through the IR Calendar page on Xenetic's website.

Will there be an opportunity for live questions during the Xenetic presentation?

There will be virtual one-on-one meetings available with management for registered investors.